Recent Updates
Recently added Catalysts
ENVB Positive Sentiment Score: 75/100

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand [Benzinga]

Thursday, May 16, 2024 1 min read
Key Takeaway: Enveric Biosciences announced its financial results for Q1 2024, highlighting a productive period focused on the development of EB-003, a neuroplastogen drug candidate. CEO Joseph Tucker emphasized the drug's potential to improve safety profiles in treating neuropsychiatric conditions. The company also reported a reduction in net loss year-over-year and an increase in cash reserves.
Price reaction · baseline $147.42 (2024-05-16T16:38:00.000Z) · hit during market hours · 2 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+9.9%
day 1
+2.6%
day 3
+1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Enveric Biosciences reported a productive first quarter.
  • Advancement of EB-003 towards IND application is promising.
  • Increased cash on hand indicates financial stability.

Full Press Release Details

Enveric Biosciences reported it financial results on Wednesday for the first quarter of 2024 ended March 31, 2024. “We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program,” said Joseph Tucker, Ph.D., director and CEO of Enveric. “EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development.”
Full Article >>

Frequently Asked Questions

What were Enveric Biosciences' Q1 2024 results?

Enveric reported a productive first quarter with reduced net loss and increased cash.

What is EB-003?

EB-003 is a neuroplastogen drug candidate aimed at improving safety in treating neuropsychiatric illnesses.

What is the significance of the IND application?

The IND application is a crucial step for Enveric to initiate clinical trials for EB-003.

Who is the CEO of Enveric Biosciences?

Joseph Tucker, Ph.D., is the director and CEO of Enveric Biosciences.

Tags: ENVB Viatris Investor Conferences Healthcare Enveric Biosciences EB-003 psychedelics neuropsychiatric financial results
Last updated: May 16, 2024

Biotech snapshot

Cash runway
$5M liquidity · $1M/mo burn
~4 mo
High dilution risk